Corticotropin is a polypeptide hormone produced and secreted by the pituitary gland. Corticotropin acts through the stimulation of cell surface the adrenocorticotropic hormone (ACTH) receptors, which are primarily located on the adrenocortical cells. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens).
Corticotropin is indicated as monotherapy for the treatment of exacerbations of multiple sclerosis in adults and infantile spasms in infants and children under 2 years of age. Controlled clinical trials have shown Corticotropin to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease. The mechanism of action of Corticotropin in the treatment of infantile spasms is unknown.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ACTHAR Approved UseH.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age; H.P. Acthar Gel is indicated for the treatment of exacerbations of multiple
sclerosis in adults; H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state. Launch Date-6.1534077E11 |
|||
| Primary | ACTHAR Approved UseH.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age; H.P. Acthar Gel is indicated for the treatment of exacerbations of multiple
sclerosis in adults; H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state. Launch Date-6.1534077E11 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [SYNDROME OF INTRACRANIAL HYPERTENSION CAUSED BY TREATMENT WITH CORTICOTROPIN]. | 1964 Jan 31 |
|
| Some observations on the hazards of corticosteroid therapy in patients with inflammatory bowel disease. | 1967 Mar-Apr |
|
| [Neuropsychiatric complications caused by cortisone and ACTH. (Clinico-social considerations)]. | 1968 Apr-Jun |
|
| Steroid myopathy complicating McArdle's disease. | 1970 Feb |
|
| Reversible cerebral atrophy and corticotrophin. | 1979 Jul 28 |
|
| Transient brain shrinkage in infantile spasms after ACTH treatment. Report of two cases. | 1980 Feb |
|
| Cerebral atrophy following ACTH therapy. | 1980 Feb |
|
| Aicardi's syndrome: are corticosteroids teratogens? | 1981 Jan |
|
| [Collateral transient behavioural changes during ACTH therapy in infantile generalized epilepsy (author's transl)]. | 1981 Mar-Jun |
|
| Sequential CT studies of 24 children with infantile spasms on ACTH therapy. | 1983 Aug |
|
| 'Dystonia'-like postural asymmetry after microinjection of ACTH N-terminal fragments but not after ACTH1-39 in rat brainstem suggests role of neuropeptide mutation in genetic movement disorder. | 1984 Feb 27 |
|
| Acute-onset transient hydrocephalus after suspension of ACTH therapy for infantile spasms: a case report. | 1984 Jun |
|
| Suppressive action of ACTH on growth hormone secretion in patients with infantile spasms. | 1985 |
|
| Cerebral blood flow and brain shrinkage seen on CT during ACTH therapy. | 1986 |
|
| Administration of ACTH to suckling rats results in hyperkinetic behavior. | 1986 |
|
| [Long-term prognosis of infantile spasms after standard ACTH treatment in Japan]. | 1986 Sep |
|
| A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus. | 1988 |
|
| ACTH and vasopressin responses to insulin-induced hypoglycemia in intact and neurohypophysectomized conscious dogs. | 1991 Jan |
|
| Infantile spasms in COFS syndrome. | 1991 Jul-Aug |
|
| Magnetic resonance imaging in infantile spasms: effects of hormonal therapy. | 1992 Mar-Apr |
|
| Activity of adenosine deaminase in red blood cells of patients suffering from multiple sclerosis treated with adrenocorticotropic hormone. | 1995 Nov-Dec |
|
| Effects of chronic 'Binge' cocaine administration on plasma ACTH and corticosterone levels in mice deficient in DARPP-32. | 1999 Sep |
|
| Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. | 2003 Apr |
|
| Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. | 2003 Jul |
|
| Inhibition of CYP17 expression by adrenal androgens and transforming growth factor beta in adrenocortical cells. | 2004 |
|
| Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. | 2005 Dec 6 |
|
| Repeated electroconvulsive stimuli increase brain-derived neurotrophic factor in ACTH-treated rats. | 2006 Jan 4 |
|
| Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. | 2008 Feb |
|
| Partial 17alpha-hydroxylase/17,20-lyase deficiency-clinical report of five Chinese 46,XX cases. | 2008 Jul |
|
| Long-term weekly ACTH therapy for relapsed West syndrome. | 2008 Jun |
|
| Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors? | 2008 May |
|
| Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature. | 2009 |
|
| The role of ether-a-go-go-related gene K(+) channels in glucocorticoid inhibition of adrenocorticotropin release by rat pituitary cells. | 2009 Jan 8 |
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 12:51:31 UTC 2023
by
admin
on
Sat Dec 16 12:51:31 UTC 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
L0378Q1565
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60238185
Created by
admin on Sat Dec 16 12:51:31 UTC 2023 , Edited by admin on Sat Dec 16 12:51:31 UTC 2023
|
PRIMARY | |||
|
SUB01466MIG
Created by
admin on Sat Dec 16 12:51:31 UTC 2023 , Edited by admin on Sat Dec 16 12:51:31 UTC 2023
|
PRIMARY | |||
|
L0378Q1565
Created by
admin on Sat Dec 16 12:51:31 UTC 2023 , Edited by admin on Sat Dec 16 12:51:31 UTC 2023
|
PRIMARY | |||
|
16132264
Created by
admin on Sat Dec 16 12:51:31 UTC 2023 , Edited by admin on Sat Dec 16 12:51:31 UTC 2023
|
PRIMARY | |||
|
6967
Created by
admin on Sat Dec 16 12:51:31 UTC 2023 , Edited by admin on Sat Dec 16 12:51:31 UTC 2023
|
PRIMARY | |||
|
C169866
Created by
admin on Sat Dec 16 12:51:31 UTC 2023 , Edited by admin on Sat Dec 16 12:51:31 UTC 2023
|
PRIMARY | |||
|
471
Created by
admin on Sat Dec 16 12:51:31 UTC 2023 , Edited by admin on Sat Dec 16 12:51:31 UTC 2023
|
PRIMARY | |||
|
9050-75-3
Created by
admin on Sat Dec 16 12:51:31 UTC 2023 , Edited by admin on Sat Dec 16 12:51:31 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
STARTING MATERIAL -> INGREDIENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|